Torasemide

ApprovedSmall molecule

Boehringer Ingelheim

Torasemide is one of 81 small molecule programs targeting Myocardial fibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial FibrosisActive, not recruiting

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

Type 2 DiabetesActive, not recruiting

Myocardial FibrosisApproved

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Heart FailureApproved

Active, not recruiting

Type 2 DiabetesPhase 1

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Torasemide

Boehringer Ingelheim

Approved

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Lovaza

AstraZeneca

Preclinical

1 7

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 8

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 9

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 10

Insulins

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Treatment

NCT06670534

Clinical

Trials by Indication[1]

Hypertension3 trials

Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

Completed·OOspedale San Raffaele·Phase 3·NCT06413082·38 enrolled

Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.

Completed·FFerrer Internacional S.A.·Phase 4·NCT00334386·388 enrolled

Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension

Completed·NNHS Greater Glasgow and Clyde·Phase 4·NCT03354897·228 enrolled

Fasting Conditions2 trials

A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:

Recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07201584·26 enrolled

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

Completed·PPharmtechnology LLC·Phase 1·NCT04921566·26 enrolled

Type 2 Diabetes1 trial

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01276288·23 enrolled

Heart Failure1 trial

The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure

Unknown status·MMedical University of Warsaw·Phase 4·NCT01942109·100 enrolled

Treatment1 trial

A Dose-finding Study of JMKX003142 in Treatment of Renal Edema

Recruiting·JJemincare·Phase 2·NCT06670534·216 enrolled

2 more indications

Myocardial fibrosis1 trial

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

Completed·FFerrer Internacional S.A.·Phase 4·NCT00409942·142 enrolled

Hemodynamic1 trial

Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.

Unknown status·SSociety of Specialists in Heart Failure·Phase 4·NCT02087332·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Torasemide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Torasemide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Torasemide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Torasemide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hypertension3 trials

Fasting Conditions2 trials

Type 2 Diabetes1 trial

Heart Failure1 trial

Treatment1 trial

Myocardial fibrosis1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News